L-Carnitine

Structure & Chemistry

L-carnitine (β-hydroxy-γ-N-trimethylaminobutyric acid) is a quaternary ammonium compound derived from the amino acids lysine and methionine. It exists as two isoforms — L-carnitine and D-carnitine — but only L-carnitine is biologically active in animals. Acetyl-L-carnitine (ALCAR) is an acetylated form with higher bioavailability and distinct neurological roles.

Biosynthesis & Sources

Endogenous synthesis: Primarily in the liver and kidneys (skeletal/cardiac muscle cannot synthesize it and depend entirely on uptake)
Dietary sources: Meat, fish, and dairy products (red meat is the richest source)
~97% of total body carnitine is stored in skeletal muscle
Homeostasis is maintained by endogenous synthesis + dietary absorption + renal reabsorption

Core Biochemical Role: The Carnitine Shuttle

The central function of L-carnitine is transporting long-chain fatty acids (LCFA) across the inner mitochondrial membrane for β-oxidation, since CoA-bound fatty acids cannot cross on their own.

Carnitine shuttle — transport of LC fatty acyl CoA across mitochondrial membranes

Figure 16.16 — The carnitine shuttle. LC fatty acyl CoA is transferred from the cytosol into the mitochondrial matrix via CPT-I, the acylcarnitine translocase, and CPT-II. (Lippincott's Biochemistry, 8th ed.)

Steps:

In the cytosol, LCFA is activated to acyl-CoA by acyl-CoA synthetase (outer mitochondrial membrane)
CPT-I (carnitine palmitoyltransferase I) transfers the acyl group from CoA to carnitine → acylcarnitine (outer membrane)
Acylcarnitine translocase transports acylcarnitine into the matrix in exchange for free carnitine
CPT-II (inner membrane) transfers the acyl group back to CoA → regenerates free carnitine and delivers acyl-CoA to the matrix for β-oxidation

Key regulation: Malonyl-CoA (the first intermediate in fatty acid synthesis) inhibits CPT-I, thereby preventing futile cycling — when fat is being made, it cannot simultaneously be degraded.

Carnitine Transporters

OCTN2 (organic cation transporter novel 2): high-affinity transporter in heart, skeletal muscle, and kidney
Liver uses a lower-affinity, higher-capacity transporter

Deficiency States

Primary Carnitine Deficiency

Cause: Autosomal recessive defect in OCTN2 → failure of cellular uptake → urinary wasting of carnitine
Features: Cardiomyopathy, skeletal muscle weakness, hypoglycemia (inability to oxidize LCFA for energy)
Treatment: Oral L-carnitine supplementation

Secondary Carnitine Deficiency

Cause	Mechanism
Chronic renal failure / hemodialysis	Loss by dialysis + impaired synthesis
Fanconi syndrome	Impaired tubular reabsorption
Liver disease (especially alcohol-induced)	Altered synthesis; alcohol-induced cirrhosis may actually raise plasma carnitine due to muscle turnover
Valproic acid use	Decreased renal reabsorption
Chronic parenteral nutrition	Lack of dietary carnitine → elevated liver enzymes early sign
CPT-I deficiency	Cannot transfer acyl group to carnitine; severe hypoglycemia during fasting
CPT-II deficiency	Most common form: exercise-induced muscle weakness + myoglobinuria

(Yamada's Gastroenterology, 7th ed.; Lippincott's Biochemistry, 8th ed.)

Clinical Applications

Approved Indications

Carnitine deficiency (primary and secondary)
End-stage renal disease / hemodialysis — L-carnitine is specifically recommended for dialysis-related carnitine deficiency
Inborn errors of metabolism involving the carnitine cycle

Investigational / Supplemental Uses

Coronary artery disease: A 2026 systematic review (PMID 41709059) suggests therapeutic potential in reducing angina, improving lipid profiles, and reducing oxidative stress in CAD
Hemodialysis lipid profile: A 2024 meta-analysis (PMID 39687901) examined effects on lipid profiles in hemodialysis patients
Female infertility: Reviewed in a 2024 umbrella review of nutrient supplements (PMID 39796491)
Exercise performance: Reduces post-exercise oxidative stress and inflammation; improves energy metabolism
Weight loss: Evidence is weak and inconsistent
Neuroprotection (ALCAR): Acetyl-L-carnitine studied in Parkinson's disease, peripheral neuropathy, and cognitive decline

Dosing

Indication	Typical Dose
Primary deficiency	50–100 mg/kg/day (oral)
Hemodialysis	20 mg/kg IV after each dialysis session, or 1–3 g/day oral
General supplementation	1–3 g/day

Safety

Generally well-tolerated
High doses may cause fishy body odor (due to trimethylamine production by gut bacteria), nausea, diarrhea
D-carnitine (as found in some supplements) competitively inhibits L-carnitine and can worsen carnitine deficiency — avoid
Caution in seizure patients (may lower seizure threshold at very high doses)

Summary: L-carnitine is an essential cofactor for mitochondrial fatty acid β-oxidation via the carnitine shuttle. It is indispensable in tissues that rely on fat oxidation (heart, skeletal muscle) but cannot synthesize it. Its supplementation is evidence-based in primary/secondary deficiency states, particularly dialysis patients, and has emerging evidence in cardiovascular disease and metabolic conditions.

This is a shared conversation. Sign in to Orris to start your own chat.